Date | Time | Source | Announcement |
---|---|---|---|
23 Feb 2006 | 07:00 AM | Notice of Results | |
03 Feb 2006 | 09:48 AM | Board Appointment | |
26 Jan 2006 | 09:46 AM | Holding(s) in Company | |
24 Jan 2006 | 08:44 AM | Holding(s) in Company | |
18 Jan 2006 | 04:13 PM | Viragen Milestone | |
04 Jan 2006 | 10:12 AM | Holding(s) in Company | |
20 Dec 2005 | 04:42 PM | Holding(s) in Company | |
19 Dec 2005 | 05:10 PM | Holding in Company Correction | |
19 Dec 2005 | 04:55 PM | Holding(s) in Company | |
19 Dec 2005 | 11:07 AM | Holding(s) in Company | |
16 Dec 2005 | 01:45 PM | Director/PDMR S/hldg-Amend | |
16 Dec 2005 | 08:23 AM | Director/PDMR Shareholding | |
15 Dec 2005 | 09:00 AM | Director/PDMR Shareholding | |
12 Dec 2005 | 12:34 PM | Holding(s) in Company | |
12 Dec 2005 | 11:24 AM | Result of EGM | |
09 Dec 2005 | 11:43 AM | Holding(s) in Company | |
08 Dec 2005 | 03:31 PM | Holding(s) in Company | |
24 Nov 2005 | 11:37 AM | Holding(s) in Company | |
22 Nov 2005 | 04:12 PM | Blocklisting Interim Review | |
22 Nov 2005 | 12:17 PM | Holding(s) in Company | |
22 Nov 2005 | 07:00 AM | TroVax Notice of Allowance | |
17 Nov 2005 | 09:35 AM | Holding(s) in Company | |
16 Nov 2005 | 04:20 PM | Publication of Prospectus | |
16 Nov 2005 | 07:01 AM | Phase II trial with TroVax | |
16 Nov 2005 | 07:01 AM | Placing and Open Offer | |
15 Nov 2005 | 11:54 AM | Holding(s) in Company | |
02 Nov 2005 | 02:22 PM | Trovax & Proposed Fundraising | |
24 Oct 2005 | 01:49 PM | Trovax Clarification | |
24 Oct 2005 | 07:00 AM | Licence Agreement | |
20 Oct 2005 | 07:00 AM | Agreement with Sigma-Aldrich | |
19 Oct 2005 | 07:00 AM | Wyeth Preclinical Data | |
18 Oct 2005 | 11:30 AM | Additional Phase II Data | |
17 Oct 2005 | 07:00 AM | Final Phase II Results | |
06 Oct 2005 | 07:00 AM | Prelim Phase II Results | |
03 Oct 2005 | 01:54 PM | Change of Adviser | |
28 Sep 2005 | 05:55 PM | Holding(s) in Company | |
20 Sep 2005 | 07:00 AM | Interim Results | |
16 Sep 2005 | 06:22 PM | Holding(s) in Company | |
07 Sep 2005 | 07:01 AM | Appointment | |
05 Sep 2005 | 07:00 AM | Notice of Results | |
25 Aug 2005 | 02:11 PM | Holding(s) in Company | |
18 Aug 2005 | 10:06 AM | Holding(s) in Company | |
17 Aug 2005 | 01:56 PM | Holding(s) in Company | |
01 Aug 2005 | 07:00 AM | Completion of Clinical Trial | |
25 Jul 2005 | 07:00 AM | Awarded Research Grant | |
06 Jul 2005 | 04:09 PM | Holding(s) in Company | |
04 Jul 2005 | 07:00 AM | Two New Patents Granted | |
30 Jun 2005 | 04:00 PM | Holding(s) in Company | |
29 Jun 2005 | 04:00 PM | Holding(s) in Company | |
17 Jun 2005 | 03:21 PM | Holding(s) in Company |
Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.
Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.
Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.